Repositorio Dspace

Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges

Mostrar el registro sencillo del ítem

dc.contributor.author Kuchay, Mohammad-Shafi
dc.contributor.author Martínez-Montoro, José-Ignacio
dc.contributor.author Choudhary, Narendra-Singh
dc.contributor.author Fernández-García, José-Carlos
dc.contributor.author Ramos-Molina, Bruno
dc.date.accessioned 2025-11-24T12:28:56Z
dc.date.available 2025-11-24T12:28:56Z
dc.date.issued 2021-10
dc.identifier.citation Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines. 28 de septiembre de 2021;9(10):1346.
dc.identifier.uri https://sms.carm.es/ricsmur/handle/123456789/22195
dc.description.abstract Non-alcoholic fatty liver disease (NAFLD), which approximately affects a quarter of the world's population, has become a major public health concern. Although usually associated with excess body weight, it may also affect normal-weight individuals, a condition termed as lean/non-obese NAFLD. The prevalence of lean/non-obese NAFLD is around 20% within the NAFLD population, and 5% within the general population. Recent data suggest that individuals with lean NAFLD, despite the absence of obesity, exhibit similar cardiovascular- and cancer-related mortality compared to obese NAFLD individuals and increased all-cause mortality risk. Lean and obese NAFLD individuals share several metabolic abnormalities, but present dissimilarities in genetic predisposition, body composition, gut microbiota, and susceptibility to environmental factors. Current treatment of lean NAFLD is aimed at improving overall fitness and decreasing visceral adiposity, with weight loss strategies being the cornerstone of treatment. Moreover, several drugs including PPAR agonists, SGLT2 inhibitors, or GLP-1 receptor agonists could also be useful in the management of lean NAFLD. Although there has been an increase in research regarding lean NAFLD, there are still more questions than answers. There are several potential drugs for NAFLD therapy, but clinical trials are needed to evaluate their efficacy in lean individuals.
dc.language.iso eng
dc.publisher MDPI
dc.rights Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/es/ *
dc.title Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
dc.type info:eu-repo/semantics/article
dc.identifier.pmid 34680463
dc.relation.publisherversion https://www.mdpi.com/2227-9059/9/10/1346
dc.identifier.doi 10.3390/biomedicines9101346
dc.journal.title Biomedicines
dc.identifier.essn 2227-9059


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta